Because of confidentiality agreements, the identities from the trial contributors stay undisclosed. Eli Lilly, the pharmaceutical firm guiding retatrutide, declined to touch upon the protocols of its ongoing trials but mentioned that patient safety is a precedence.Early final results advise retatrutide could give even better metabolic benefits that